Surrogacy of progression free survival for overall survival in metastatic breast cancer studies: meta-analyses of published studies (1608.04300v2)

Abstract: Purpose: PFS is often used as a surrogate endpoint for OS in metastatic breast cancer studies. We have evaluated the association of treatment effect on PFS with significant HR${OS}$ (and how this association is affected by other factors) in published prospective metastatic breast cancer studies. Methods: A systematic literature search in PubMed identified prospective metastatic breast cancer studies. Treatments effects on PFS were determined using hazard ratio (HR${PFS}$), increase in median PFS ($\Delta$MED${PFS}$) and % increase in median PFS (%$\Delta$MED${PFS}$). Diagnostic accuracy of PFS measures (HR${PFS}$, $\Delta$MED${PFS}$ and %$\Delta$MED${PFS}$) in predicting significant HR${OS}$ was assessed using receiver operating characteristics (ROC) curves and classification trees approach. Results: Seventy-three cases (i.e., treatment to control comparisons) from 64 individual publications were identified for the analyses. Of these, 16 cases reported significant treatment effect on HR${OS}$ at 5% level of significance. Median number of deaths reported in these cases were 156. Area under the ROC curve (AUC) for diagnostic measures as HR${PFS}$, $\Delta$MED${PFS}$ and %$\Delta$MED${PFS}$ were 0.69, 0.70 and 0.75, respectively. Classification tree results identified %$\Delta$MED${PFS}$ and number of deaths as diagnostic measure for significant HR${OS}$. Only 7.9\% (3/39) cases with $\Delta$MED${PFS}$ shorter than 48.27\% reported significant HR${OS}$. There were 7 cases with $\Delta$MED${PFS}$ of 48.27\% or more and number of deaths reported as 227 or more -- of these 5 cases reported significant HR${OS}$. Conclusion: %$\Delta$MED${PFS}$ was found as better diagnostic measure for significant HR${OS}$. Our analysis results also suggest that consideration of total number of deaths may further improve its diagnostic performance.